Latest Breaking News On - ம்ஸ்ந் குழு - Page 1 : comparemela.com

HYDERABAD: Hyderabad-based MSN Labs (MSN) on Thursday said it has entered into a royalty-free, non-exclusive, voluntary license agreement with US drug giant Eli Lilly & Co for manufacturing and marketing Covid-19 treatment drug Baricitinib in India. MSN said it will be launching the product under the brand name Baridoz in two strengths 2 mg & 4mg. The company has also developed the active pharmaceutical ingredient and the formulation of Baricitinib in its in-house R&D and manufacturing units, it said. The rheumatoid arthritis drug Baricitinib has been granted a restricted emergency use approval in India by the Central Drugs Standard Control Organization (CDSCO) for emergency use in combination with Remdesivir for the treatment of suspected or laboratory confirmed Covid-19 in hospitalised adults requiring supplemental oxygen, invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Andhra pradeshOselow oseltamivirCentral drugs standard control organizationEli lilly coEli lillyNdia newsNdia news todayOday newsGoogle newsReaking newsMsn groupEli lilly amp coஆந்திரா பிரதேஷ்மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்எலி லில்லி இணைஎலி லில்லி